James T. Parsons serves as Executive at DiaMedica Therapeutics Inc., where they oversee executive responsibilities. Since joining the company, James T. Parsons has executed 8 insider transactions totaling $143.3K, demonstrating a bearish approach to their equity position. Their most recent transaction on Nov 21, 2025 involved exercising options for 12,000 shares valued at $26.4K.
James T. Parsons currently holds 87,854 shares of DiaMedica Therapeutics Inc. (DMAC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, James T. Parsons has been a net seller of DMAC stock. They have purchased $9.0K and sold $134.3K worth of shares.
James T. Parsons's most recent insider trade was on Nov 21, 2025, when they sold 12,000 shares at $2.20 per share.
Get notified when new Form 4 filings are submitted
| 21,428 |
| $2.80 |
| Discretionary |
| Jan 3, 2022 | DMAC | $60.0K | Award | 16,773 | $3.58 | Discretionary |
| Jan 8, 2021 | TRIL | $61.6K | Option Exercise | 8,505 | $7.24 | Discretionary |
| Jan 8, 2021 | TRIL | $134.3K | Sale | 8,505 | $15.79 | Discretionary |
| Jan 1, 2021 | DMAC | $63.7K | Award | 7,745 | $8.23 | Discretionary |
| Jun 1, 2020 | DMAC | $37.2K | Award | 8,102 | $4.59 | Discretionary |
| Dec 11, 2018 | DMAC | $9.0K | Purchase | 2,250 | $4.00 | Discretionary |